Smith & Nephew rebuffs bid from J & J

Share this article:

Wound care firm Smith & Nephew rejected a $10.9 billion acquisition offer from Johnson & Johnson.

Smith & Nephew CEO David Illingworth declined to comment on the bid, sending his firm's stock prices soaring by more than 10%. “Speculation has been going on for 10 years,” he said at a J.P. Morgan Healthcare Conference in San Francisco.

J&J spokesman Jeff Leebaw also declined comment.

Sky News reported that Johnson & Johnson approached its rival in December with the  11-figure proposal. But the outlet did not cite sources, or indicate where it had received its information.

Johnson & Johnson was considering whether or not to come back with a raised offer, according to several other published reports.

The allegation that Smith & Nephew received and rejected a bid without informing shareholders reopened debate on when companies should be required to make bids known to the market.

It is generally accepted that companies should not have to reveal all bids received. Some argue that there must be something wrong with the system if boards can withhold information about serious bids.
Share this article:

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.